Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab versus placebo and etanercept in moderate to severe chronic plaque psoriasis
2010-022228-66Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in psoriasis and plaque psoriasis (3 arms), sponsored by Novartis. Primary endpoints: PASI and IGA. Started Mar 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2010-022228-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022228-66.